NVAX NVAX

Novavax Stock Price

17.035
0.515 (3.12%)
Upgrade to Real-Time
Regular Market
17.035
Volume 4,631,817
Bid Price 17.03
Ask Price 17.05
News -
Day High 17.96

Low
15.53

52 Week Range

High
236.50

Day Low 16.40
Company Name Stock Ticker Symbol Market Type
Novavax Inc NVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.515 3.12% 17.035 13:29:02
Open Price Low Price High Price Close Price Prev Close
16.44 16.40 17.96 16.52
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
37,428 4,631,817 $ 17.42 $ 80,701,922 - 15.53 - 236.50
Last Trade Time Type Quantity Stock Price Currency
13:29:02 100 $ 17.035 USD

Period:

Draw Mode:

Novavax Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.34B 78.50M 78.25M $ 1.15B $ -988.33M -23.42 -0.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 23.02k 2.20%

more financials information »

Novavax News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NVAX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week16.4718.061515.5316.665,575,2920.5653.43%
1 Month19.5225.6515.5319.254,722,936-2.49-12.73%
3 Months32.0333.3715.5320.765,126,007-15.00-46.82%
6 Months45.3176.7715.5338.046,027,904-28.28-62.4%
1 Year151.90236.5015.5364.285,767,371-134.87-88.79%
3 Years4.92331.53883.651896.605,766,45312.12246.24%
5 Years28.40331.53883.5467.256,140,236-11.37-40.02%

Novavax Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.